Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11739-020-02432-x http://scihub22266oqcxt.onion/10.1007/s11739-020-02432-x 32653981!7352087!32653981     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intern+Emerg+Med 2020 ; 15 (8): 1375-1387 Nephropedia Template TP {{tp|p=32653981|t=2020. COVID-19, coagulopathy and venous thromboembolism: more questions than answers |pdf=|usr=}}{{32653981}} gab.com Text COVID-19, coagulopathy and venous thromboembolism: more questions than answers JO: Intern Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=32653981 #FOAvip The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. However, some relevant issues on the relationships between COVID-19, coagulopathy and VTE have yet to be fully elucidated. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? How do we frame the COVID-19 associated coagulopathy? Which role, if any, do antiphospolipid antibodies have? How do we tackle COVID-19 coagulopathy? In the complex scenario of an overwhelming pandemic, most everyday clinical decisions have to be taken without delay, although not yet supported by a sound scientific evidence. This review discusses the most recent findings of basic and clinical research about the COVID-associated coagulopathy, to foster a more thorough knowledge of the mechanisms underlying this compelling disease. Twit Text FOAVip COVID-19, coagulopathy and venous thromboembolism: more questions than answers ????Intern Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=32653981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32653981 #FOAvip English Wikipedia <ref>{{Cite pmid|32653981}}</ref> COVID-19, coagulopathy and venous thromboembolism: more questions than answers #MMPMID32653981 Marietta M; Coluccio V; Luppi M Intern Emerg Med 2020[Nov]; 15 (8): 1375-1387 PMID32653981show ga The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. However, some relevant issues on the relationships between COVID-19, coagulopathy and VTE have yet to be fully elucidated. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? How do we frame the COVID-19 associated coagulopathy? Which role, if any, do antiphospolipid antibodies have? How do we tackle COVID-19 coagulopathy? In the complex scenario of an overwhelming pandemic, most everyday clinical decisions have to be taken without delay, although not yet supported by a sound scientific evidence. This review discusses the most recent findings of basic and clinical research about the COVID-associated coagulopathy, to foster a more thorough knowledge of the mechanisms underlying this compelling disease. |Blood Coagulation/drug effects/*physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/epidemiology/physiopathology[MESH] |Disseminated Intravascular Coagulation/etiology[MESH] |Fibrinolytic Agents/therapeutic use[MESH] |Heparin, Low-Molecular-Weight/therapeutic use[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/epidemiology/physiopathology[MESH]COVID-19, coagulopathy and venous thromboembolism: more questions than(epmc).pdf DeepDyve Pubget Overpricing